Karuna Therapeutics, Inc.
(NASDAQ : KRTX)

( )
KRTX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.57%145.950.7%$900.06m
PFEPfizer Inc. 0.59%37.680.9%$771.65m
MRKMerck & Co., Inc. 0.69%79.750.7%$631.99m
BMYBristol-Myers Squibb Co. 0.15%60.851.0%$616.05m
ABBVAbbVie, Inc. 0.01%84.311.9%$612.58m
LLYEli Lilly & Co. 0.04%141.651.1%$485.78m
AZNAstraZeneca Plc 0.71%52.331.2%$204.87m
GSKGlaxoSmithKline Plc 0.83%35.380.2%$144.81m
NVSNovartis AG -0.05%84.410.2%$141.06m
NVONovo Nordisk A/S -0.01%70.880.1%$70.24m
RGENRepligen Corp. 0.00%176.517.1%$66.60m
RPRXRoyalty Pharma Plc 1.00%39.600.2%$66.17m
SNYSanofi 1.27%49.550.2%$50.03m
AMAGAMAG Pharmaceuticals, Inc. 0.00%13.6622.1%$45.33m
OPKOPKO Health, Inc. 0.94%4.3111.2%$41.70m

Company Profile

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders.The company was founded in July 2009 by Andrew Miller, Eric Elenko and Peter Jeffrey Conn and is headquartered in Boston, MA.